Why Biosimilars and Orphan Drugs Are Dodging 2026 US Pharma Tariffs for Now
Biosimilars, generic medicines and certain orphan drugs currently sit outside the harshest 2026 Section 232 pharmaceutical tariffs. But a mandated generics review could determine how durable that protection really is.



